Boehringer Ingelheim and Genentech have announced the early termination of ASSENT 4 PCI,

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1061, 2005-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tiotropium bromide [Spiriva; Boehringer Ingelheim] and peginterferon- -2b plus ribavirin [Peg-Intron plus Rebetol; Schering-Plough] have been recommended for approval

By  

Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Tiotropium bromide [Spiriva; Boehringer Ingelheim] has received final approval in Japan

By  

Inpharma, Vol. 1, Iss. 1465, 2004-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Boehringer Ingelheim Canada has issued a `Dear Health Care Professional' letter regarding intracranial haemorrhage (ICH) in patients receiving Aptivus

By  

Reactions Weekly, Vol. 1, Iss. 1110, 2006-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

The average wholesale price (AWP) at which Pfizer and Boehringer Ingelheim are launching tiotropium bromide [Spiriva] is 30% less than the AWP of GlaxoSmithKline's salmeterol/fluticasone propionate [Advair]

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 454, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

South Africa is likely to withdraw approval of nevirapine in the prevention of mother-to-child transmission (MTCT) of HIV infections unless Boehringer Ingelheim produces new data to support the use of the drug in this indication

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 425, 2003-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite